ClinicalTrials.gg
Active, not recruitingNCT06964061Updated Jul 7, 2026

Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Phase 1 interventional study of PA5436 Ocular Implant, 115mcg in Open Angle Glaucoma (OAG) and Ocular Hypertension (OH), sponsored by PolyActiva Pty Ltd. Active, not recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by PolyActiva Pty Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Glaucoma, Open-Angle with a site in Australia — none open to participants now, 2 under way, none of them phase 3. Glaucoma, Open-Angle · Australia.

Planned enrollment
13th of 14
12 · median 84
Started
2025
with 1 other
Phase 1
4 of 14
none open now
Registered
14th of 14
by date
Lead sponsor
3 of 14
PolyActiva Pty Ltd

Among the 14 studies in Glaucoma, Open-Angle with a site in Australia, this one is the 13th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 1, and was the 14th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 14 studies in Glaucoma, Open-Angle with a site in Australia is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Glaucoma, Open-Angle with a site in Australia as a file.
02

Study summary

The goal of this clinical study is to learn how effective and safe is a single administration of PA5346 Ocular Implant for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. It will also assess how long it takes for PA5346 Ocular Implant to dissolve in the eye.

Read the detailed description

This is an open-label study that will evaluate the efficacy, safety, tolerability and biodegradation of PA5346 Ocular Implant administered as a single dose at 115mcg in adults with open-angle glaucoma or ocular hypertension.

The study plans to recruit approximately 12 participants. Eligible participants will receive a single PA5346 Ocular Implant administered into the intracameral space of the study eye and followed for approximately 52 weeks at a minimum or until the implant is no longer visible in the study eye.

03

Conditions studied

  • Open Angle Glaucoma (OAG)
  • Ocular Hypertension (OH)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to provide and follow study instructions
  • 18 years of age or older
  • Diagnosis of open-angle glaucoma or ocular hypertension in both eyes
  • Qualifying IOPs across 2 visits following washout of IOP-lowering medication, if applicable
  • Qualifying best-corrected visual acuity BCVA using Early Treatment Diabetic Retinopathy Study (ETDRS) chart in study eye
  • Qualifying corneal endothelial cell density (CEDC) in the study eye

Key Exclusion Criteria:

  • Pseudoexfoliation or pigment dispersion, narrow irido-corneal drainage angles, or existing peripheral anterior synechiae in the inferior angle either eye.
  • Advanced or severe glaucoma
  • Disqualifying central corneal thickness in either eye
  • Significant other ocular conditions that could prevent accurate assessment of IOP and corneal health
  • Uncontrolled medical conditions
  • Have previously received, any injectable glaucoma medication into the anterior chamber of the study eye
  • Have received intravitreal injections in the study eye within the last 3 months of the Screening Visit and anticipated need for an intravitreal injection during the course of the study
  • Unwilling or unable to discontinue, in either eye, soft contact lens wear at least 2 days and hard contact lens wear 1 week before scheduled study visits and on implant administration days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    PA5436 Ocular Implant, 115mcg

    PA5436 Ocular Implant, 115mcg administered by the Investigator into the anterior chamber of the study eye through a clear corneal injection

    Combination Product: PA5436 Ocular Implant, 115mcg

Interventions

  • Combination productPA5436 Ocular Implant, 115mcg

    The PA5346 Ocular Implant is supplied preloaded into the needle of a single use Administration Device ready for use.

06

What researchers measure

Primary outcomes

  1. Efficacy: change in mean diurnal intraocular pressure in study eye

    Time frame: Weeks 2, 12, 26 and 52

  2. Incidence of ocular symptoms and ocular treatment-emergent adverse events

    Ocular safety and tolerability (AEs)

    Time frame: Day 1 through study completion at least until Week 52

Secondary outcomes

  1. Efficacy: intraocular pressure change from baseline in study eye at different diurnal time points.

    Time frame: Weeks 2-52

Other outcomes

  1. Time to complete biodegradation of the implant assessed by gonioscopy

    Time frame: Day 1 through study completion at least until Week 52

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 20 months after the start.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's planned 20 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
May 9, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Feb 15, 2027
CompletionEst.
Apr 15, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06964061
Lead sponsor
PolyActiva Pty Ltd
Responsible party
Sponsor
First posted
May 9, 2025
Start date
Jun 10, 2025
Primary completion
Feb 15, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Jul 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion